Qed Therapeutics, A Bridgebio Company
Clinical trials sponsored by Qed Therapeutics, A Bridgebio Company, explained in plain language.
A biotech subsidiary of BridgeBio developing targeted therapies for genetic diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Could a daily pill boost growth in kids with hypochondroplasia?
Disease control ENROLLING_BY_INVITATIONThis study tests an oral drug called infigratinib in children with hypochondroplasia, a condition that causes short stature. The trial has two parts: first, all children receive the drug to see if it safely increases their growth rate; then, some will switch to a placebo to confi…
Phase: PHASE2, PHASE3 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Hope for kids with rare bone disorder: new drug shows promise in Long-Term trial
Disease control ENROLLING_BY_INVITATIONThis study is for children with hypochondroplasia, a condition that causes short stature and bone differences. Researchers are testing a drug called infigratinib to see if it is safe and helps improve growth over the long term. Participants must have already completed a previous …
Phase: PHASE2 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New oral drug shows promise for helping children with dwarfism grow
Disease control ENROLLING_BY_INVITATIONThis study tests a daily oral drug called infigratinib in 300 children with achondroplasia, the most common form of dwarfism. The drug aims to improve bone growth by targeting a specific protein. Researchers will monitor safety and growth over several years, including children wh…
Phase: PHASE2 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC